Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Size, Share & Trends Analysis by Disease (Neurological Disorders and Dystrophies, Cardiac disorders, Retinal Eye Disease, Metabolic Disorders, Liver disease, Others), Products and Services (Disease Model, Reprogramming service, Differentiation service, Screening service, Characterization service, Others), and Segment Forecasts, 2023-2031

Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model   Market Size is predicted to grow at an 11.2% CAGR during the forecast period for 2024-2031.

Human-induced pluripotent stem cells (hiPSCs) are a pivotal tool in biomedical research, particularly for preclinical disease modelling and drug development. Derived from adult somatic cells like skin or blood cells, hiPSCs are reprogrammed to an embryonic-like pluripotent state. This transformation enables them to differentiate into various cell types, including those affected by specific diseases. Therefore, hiPSCs provide a potent substrate for the investigation of disease mechanisms at the cellular level and the evaluation of potential therapies in controlled laboratory environments. One significant application of hiPSCs is their ability to generate disease-specific cell lines from patients, allowing for personalized disease modelling and tailored drug screening. By differentiating hiPSCs into affected cell types such as cardiomyocytes, neurons, or pancreatic beta cells, researchers can closely investigate disease pathology and explore therapeutic interventions. Moreover, hiPSCs can be genetically modified to correct disease-causing mutations, providing insights into how genetic alterations contribute to disease progression and offering a foundation for developing gene therapies.

The expansive disease modeling capacity of human-induced pluripotent stem cells (hiPSCs) stands as a pivotal driver in the preclinical disease model market. With the ability to simulate a wide array of conditions such as cardiovascular disorders, neurological ailments, and metabolic diseases, hiPSCs offer unmatched versatility. This capability not only enhances our comprehension of disease mechanisms but also accelerates the development and testing of novel therapeutic interventions.

Competitive Landscape

Some of the Key Players in Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market:

• Axol Bioscience Ltd
• DefiniGEN
• REPROCELL
• The Jackson Laboratory
• Creative Biolabs
• Cyagen
• FUJIFILM Cellular Dynamics
• ElevateBio
• Bio-Techne
• BPS Bioscience, Inc.
• Catalent, Inc
• Ncardia
• NEXEL Co
• Evotec's
• iXCells Biotechnologies
• Elixirgen
• Other Prominent Players

Market Segmentation:

The human-induced pluripotent stem cells (hiPSCs) preclinical disease model market is segmented by disease, products and services. By disease, the market is segmented into neurological disorders and dystrophies, cardiac disorders, retinal eye disease, metabolic disorders, liver disease, and others. The products and services market is categorized into disease model, reprogramming service, differentiation service, screening service, characterization service, and others.

Neurological Disorders And Dystrophies Segment Holds Significant Market Share In The Market.

The neurological disorders segment is a driving force in the human induced pluripotent stem cells (hiPSCs) preclinical disease model market for several compelling reasons. Conditions such as Parkinson's, Alzheimer's, Huntington's, ALS, schizophrenia, and various neurodevelopmental disorders represent significant focal points for hiPSC-based disease modelling. HiPSCs offer the unique ability to generate disease-specific cell lines and differentiate into key affected cell types like neurons and glia, providing invaluable insights into neurological disease mechanisms and accelerating drug discovery efforts. Compared to other disease areas, the successful implementation of hiPSC-based models has been particularly pronounced in neurology, likely due to the urgent need for therapeutic advancements and the unprecedented ability of hiPSCs to closely mimic patient-specific disease conditions.

The Disease Model Segment Is Growing At The Highest Rate In The Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market.

The human-induced pluripotent stem cells (hiPSCs) preclinical disease model market is experiencing significant growth, particularly in Disease Modeling for neurological disorders and cardiac diseases. This growth is fueled by several factors identified in recent searches. Firstly, hiPSC-based models have demonstrated notable success in unravelling the mechanisms of neurological disorders like Parkinson's, Alzheimer's, Huntington's, ALS, and neurodevelopmental conditions, addressing critical gaps in disease understanding. Secondly, there is a shift towards utilizing hiPSC-based models as alternatives to animal testing in preclinical trials, aiming for more predictive endpoints that align better with human physiology and regulatory standards.

Regionally, North America Led The Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market.

North America's hiPSCs preclinical disease model market is increasing due to robust pharmaceutical and biotech sectors, particularly in the U.S. These industries are actively adopting hiPSC-based technologies for drug development. Supported by a favourable regulatory environment and significant funding from entities like the NIH, alongside leading research institutions such as Harvard and Stanford, North America remains at the forefront of advancing hiPSC-based disease modelling and biomedical innovation.

Recent Developments:

• In May 2024, REPROCELL will now offer Master Cell Bank (MCB) manufacturing services for Human Induced Pluripotent Stem Cells (hiPSCs) and Human Mesenchymal Stem Cells (hMSCs) tailored for human therapeutic applications. Our process includes stringent control from donor recruitment to seed stock hiPSC production, ensuring compliance with regulatory agencies across various geographical regions.

• In August 2022, ElevateBio, LLC partnered with George Daley, M.D., Ph.D., and Boston Children's Hospital to establish a novel startup. The objective of this endeavor is to provide allogeneic immune cell therapies by utilizing a new platform that generates fully developed immune cells from induced pluripotent stem cells (iPSCs). This novel method tackles the issue of iPSCs commonly producing undeveloped embryonic blood cell types, guaranteeing the production of many mature immune cell subtypes that possess molecular properties resembling adult T cells obtained from blood.

Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model   Market Report Scope

Segmentation of Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model   Market -

Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market by Disease-

• Neurological Disorders and Dystrophies
• Cardiac Disorders
• Retinal Eye Disease
• Metabolic Disorders
• Liver Disease
• Others

Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market by Products and Services-

• Disease Model
• Reprogramming Service
• Differentiation Service
• Screening Service
• Characterization Service
• Others

Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market by Region-

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa
• Rest of the Middle East and Africa